Delving into the Latest Updates on Carvedilol with Synapse

Overview

Basic Info

SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions.

Drug Type

Small molecule drug

Synonyms

Carvedilol (JP17/USP/INN), Corever, Pluscor

+ [28]

Target

ADRA1 x adrenergic receptor x β1-adrenergic receptor x β2-adrenergic receptor

Action

antagonists

Mechanism

ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesUrogenital Diseases+ [1]

Active Indication

Atrial FibrillationAngina, StableHeart Failure+ [5]

Inactive Indication

Chronic heart failureDrug Resistant EpilepsyHypertrophy, Left Ventricular+ [3]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

Daiichi Sankyo Co., Ltd.InnoPharmax, Inc.Alvogen Korea Co., Ltd.

+ [1]

Inactive Organization

Chong Kun Dang Pharmaceutical Corp.

TSH Biopharm Corp., Ltd.

GSK Plc

License Organization

Smithkline Beecham

TSH Biopharm Corp., Ltd.

Shandong New Time Pharmaceutical Co. Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

Japan (19 Jan 1993),

Angina PectorisEssential HypertensionHypertension, Renal

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H26N2O4

InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N

CAS Registry72956-09-3

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

Start Date15 May 2025

Sponsor / Collaborator

University of Rochester

[+1]

NCT06844669

/ RecruitingPhase 2IIT

HER2HEART-US: Primary Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy: a Pilot 2x2 Factorial Randomized Controlled Trial

Ten to 15% of patients with breast cancer are HER2 positive, with treatment focused on targeting the HER2 receptor. Although these treatments are generally well tolerated, they are associated with an increased risk of cardiomyopathy. There are currently no treatments proven to prevent the cardiotoxicities associated with HER2-targeted therapy, but there is convincing preclinical data demonstrating that prophylactic treatment with a beta blocker (BB) and/or an SGLT2 inhibitor (SGLT2i) may each independently prevent cardiotoxicity and HER-targeted treatment interruptions.
The proposed pilot study will assess the feasibility and preliminary efficacy and safety of therapy with both a beta blocker (carvedilol) and an SGLT2 inhibitor (empagliflozin), alone and in combination, in a population initiating HER2-directed therapy for HER2+ breast cancer.
The hypotheses being tested in this study are:
1. It is feasible to recruit 20-40 patients over 6 months
2. There are no differences in tolerability and safety between participants taking carvedilol and/or empagliflozin and those receiving usual care.

Start Date16 Apr 2025

Sponsor / Collaborator

Washington University School of Medicine

TCTR20250409002

/ Not yet recruitingPhase 1

A Bioequivalence Study of Two Formulations of Carvedilol 12.5 mg Tablets in Healthy Thai Subjects under Fed Conditions

Start Date08 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Carvedilol

Login to view more data

100 Translational Medicine associated with Carvedilol

Login to view more data

100 Patents (Medical) associated with Carvedilol

Login to view more data

7,047

Literatures (Medical) associated with Carvedilol

01 Jul 2025·AMERICAN HEART JOURNAL

Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial

Article

Author: Fialho, Guilherme Loureiro ; Hajjar, Ludhmila Abrahao ; Furtado, Remo H M ; Dent, Susan ; Bacchiega, Bruno C ; Drager, Luciano F ; Cauduro, Sanderson ; Walter, Edilson ; Gibson, C Michael ; de Mattos, Renata Rodrigues ; Rehder, Marilia Harumi H S ; Barbosa, Lilian M ; Saretta, Roberta ; Silva, Ana Cecilia Alcantara ; de Barros E Silva, Pedro Gabriel Melo ; Damiani, Lucas P ; Luz, Mariane Nascimento ; Costa, Isabela Bispo Santos da Silva ; Melo, Marcelo Dantas Tavares de ; Kalil Filho, Roberto ; Silvestre, Odilson ; Lopes-Fernandez, Teresa ; Lopes, Renato D ; Araruna, Paula

BACKGROUND:

Patients with cancer undergoing chemotherapy with an anthracycline-based regimen are at increased risk of cardiotoxicity, predisposing to heart failure, arrhythmias and death. Whether carvedilol may confer benefit to prevent anthracycline-induced cardiotoxicity remains to be determined.

DESIGN:

CARDIOTOX is a double-blind, placebo controlled randomized clinical trial that plan to enroll 1,018 patients across 25 study sites in Brazil. Patients with active cancer scheduled to undergo an anthracycline-based chemotherapy regimen are eligible. Patients with prior HF or cardiomyopathy are excluded. Patients are randomized in 1:1 ratio to carvedilol (starting dose 6.25mg BID up titrated to 25mg BID or maximum tolerated dose) or placebo, stratified by site and use of renin-angiotensin blockers at baseline. Study drug is administered through the duration of chemotherapy and up to 30 days after the last dose of anthracycline. Patients are scheduled to undergo echocardiographic evaluations at baseline and at 3, 6, and 12 months. The study primary endpoint is the composite of new left ventricle ejection fraction (LVEF) reduction by at least 10% leading to an LVEF <50%, cardiovascular death, myocardial infarction, urgent care visit or hospitalization for heart failure, or clinically significant arrhythmias at 12 months. Echocardiographic images will be analyzed by a central core lab, clinical outcomes will be adjudicated, and safety endpoints include serious adverse events and adverse events of special interest (symptomatic bradycardia, hypotension, syncope and bronchospasm).

SUMMARY:

The CARDIOTOX trial is the largest trial to date analyzing the potential role of beta-blockers as prophylactic therapy to prevent cardiotoxicity induced by anthracyclines.

TRIAL REGISTRATION:

Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy (CardioTox).

CLINICALTRIALS:

gov ID NCT04939883. https://clinicaltrials.gov/study/NCT04939883.

01 Jun 2025·ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial)

Article

Author: Tripathi, Dhiraj ; Richardson, Paul ; Poyner, Christopher ; Mathers, Jonathan ; Holden, Lisa ; Jowett, Sue ; Abdali, Zainab ; Rowe, Ian ; Ferguson, James ; Handley, Kelly

ABSTRACT:

Background:

The superior efficacy of non‐selective beta‐blockers (NSBB) compared with variceal band ligation (VBL) in the primary prevention of variceal bleeding is uncertain.

Aim:

To compare carvedilol versus VBL for primary prevention of variceal bleeding.

Methods:

CALIBRE was an investigator‐initiated, multicentre, randomised, controlled, open‐label trial. Participants were randomly assigned to 12.5 mg carvedilol once daily or VBL. Inclusion criteria were cirrhosis and medium to large oesophageal varices that had not bled. The primary outcome is any variceal bleeding within 1 year of randomisation. Secondary outcomes include survival, other complications of cirrhosis, quality of life, cost‐effectiveness and adverse events. Recruitment closed early, mainly due to the impact of the pandemic.

Results:

265 participants (10% of the intended sample size) from 52 sites were randomised to carvedilol (n = 133) or VBL (n = 132) between 22 January 2019 and 31 August 2022. 5/133 participants (3.8%) in the carvedilol arm vs. 10/132 participants (7.6%) in the VBL arm experienced variceal bleeding (risk ratio 0.50 (95% confidence interval [CI]; 0.17–1.41); risk difference − 0.038 (95% CI; −0.094—0.017)). Serious adverse events occurred in one participant in each treatment arm, with no treatment‐related deaths. Of the secondary outcomes, there were no statistically significant differences. Carvedilol was cheaper and resulted in slightly more quality‐adjusted life years than VBL.

Conclusions:

The early terminated and, thus, underpowered CALIBRE trial showed no difference between carvedilol and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium‐to large‐sized oesophageal varices. No untoward safety concerns were noted.

Trial Registration:

ISRCTN73887615

01 Jun 2025·CARBOHYDRATE POLYMERS

Bespoke hydroxypropyl methylcellulose-based solid foams loaded with poorly soluble drugs by tunable modular design

Article

Author: Mu, Huiling ; He, Wuzhong ; Genina, Natalja

A tunable modular design (TMD) as a new approach was proposed to tailor the dose and drug release profile of poorly water-soluble drugs from hydroxypropyl methylcellulose (HPMC)-based solid foams by combining two manufacturing principles: (1) freeze-drying aqueous HPMC-based gels to yield porous sturdy modules with specific doses of an active pharmaceutical ingredient (API) with the step size of 3 mg, and (2) fine-tuning the desired dose of the API with the step size of 0.1 mg by inkjet printing of the API-loaded ink onto the modules. Carvedilol (CAR) was used as a model poorly water-soluble API that requires frequent dose adjustment. The limitation of poor CAR solubility was overcome by designing pharmaceutically approved co-solvent systems. This approach ensured printable inks of a high drug content, and sturdy and flexible modules with uniform distribution of CAR to achieve effective and accurate doses of CAR. The tailored release rate of CAR from TMD products was succeeded by varying the composition, particularly, the content and grade of HPMC, and physical dimensions of modules. The TMD approach holds potential for designing bespoke high-quality products, containing hydrophilic cellulose ethers such as HPMC and poorly water-soluble APIs.

22

News (Medical) associated with Carvedilol

15 Feb 2024

·www.businesswire.com

GoodRx Now Offering 30 Common Heart Health Medications for Under $30

SANTA MONICA, Calif.--( BUSINESS WIRE )-- GoodRx , the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide. 1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That’s why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and brand-name medications that mitigate the risk and impact of cardiovascular conditions such as coronary artery disease, high cholesterol, hypertension, and more. By helping people afford their prescriptions, GoodRx is improving health outcomes and reducing the overall strain on the healthcare system. GoodRx’s recent report - The GoodRx Effect - estimates that GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits and 110,000 hospitalizations for major adverse cardiovascular events like heart attack and stroke. Save an average of 84% on common generic medications 2 The following is a sample list of common generic medications used to treat cardiovascular disease that are available for under $30 on GoodRx. MEDICATION LOWEST PRICE 3 AVG % SAVINGS 4 ACE Inhibitors Lisinopril (generic Prinivil and Zestril) $9.29 67% Enalapril (generic Epaned and Vasotec) $15.54 75% Beta Blockers Carvedilol (generic Coreg) $10.68 75% Metoprolol ER (generic Toprol XL) $11.15 74% Propranolol (generic Inderal) $10.96 71% Calcium Channel Blockers Amlodipine (generic Amvaz, Katerzia, and Norvasc) $9.15 80% Diltiazem ER (generic Cardizem CD) $13.43 74% Statins Atorvastatin (generic Lipitor) $10.10 83% Pravastatin (generic Pravachol) $14.53 74% Rosuvastatin (generic Crestor) $10.57 91% Access exclusive discounts and savings on brand-name drugs GoodRx offers incredible savings on brand-name medications that are often more costly and harder to obtain: MEDICATION SAVINGS* Entresto Pay as little as $10 for up to a 90-day supply Jardiance Pay as little as $10 per month Lodoco Pay as little as $30 for up to a 90-day supply Ozempic Pay as little as $25 per month Repatha Pay as little as $5 per month Soaanz Exclusive discount to save over 70% Toprol XL Exclusive discount to save up to 51% Xarelto Pay as little as $10 per fill *May require private or commercial insurance Learn more about cardiovascular disease from trusted doctors, pharmacists and health experts GoodRx Health is a go-to resource for understanding common heart conditions, risk factors, treatment options and associated savings. The GoodRx Heart Health Center provides credible, timely and actionable information to help people better manage their health. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more. “Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD , Medical Editor at GoodRx. “Knowledge is power, so we create easy-to-understand content that people can actually use so they are better equipped to minimize the risk of disease, find affordable medications, stick to their treatment plans, and ultimately improve their overall health and wellbeing.” To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com/hearthealth . About GoodRx GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade. GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com . We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers, the U.S. healthcare system and GoodRx; and GoodRx’s plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. 1 Prices are subject to change at any time without notice. Prices may vary at different pharmacies, and for different forms, dosages, and quantities. 2 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023. 3 As of February 1, 2024. 4 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023.

AHA

12 Jan 2024

·www.drugs.com

Drug May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

12 Jan 2024

·www.drugs.com

Carvedilol May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

100 Deals associated with Carvedilol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00255	Carvedilol	C07AG02	DB01136

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Atrial Fibrillation	Japan	Daiichi Sankyo Co., Ltd.	24 Aug 2015
Angina, Stable	South Korea	Alvogen Korea Co., Ltd.	06 Nov 2001
Heart Failure	United States	Waylis Therapeutics LLC	14 Sep 1995
Hypertension	United States	Waylis Therapeutics LLC	14 Sep 1995
Ventricular Dysfunction, Left	United States	Waylis Therapeutics LLC	14 Sep 1995
Angina Pectoris	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Essential Hypertension	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Hypertension, Renal	Japan	Daiichi Sankyo Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Drug Resistant Epilepsy	Phase 3	United States	GSK Plc	01 Dec 2008
Left ventricular systolic dysfunction	Phase 3	United States	-	01 Oct 2005
Hypertrophy, Left Ventricular	Phase 3	United States	GSK Plc	01 Jan 2005
Chronic heart failure	Phase 3	United States	GSK Plc	01 Jan 2002
Pulmonary Arterial Hypertension	Phase 2	United States	GSK Plc	01 Jun 2010
Metabolic Syndrome	Phase 1	United Kingdom	GSK Plc	15 Jan 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04023110 (CCT guide, Pubmed \| Breast Cancer Res Treat)	Phase 1	Breast Cancer	68	Carvedilol	bfoxvcdfxb(adbrbrwhid) = jtyzcmhgdi yczexsxkkt (xvtldwlpxc )	Positive	02 Apr 2025
				carvedilol (Usual care)	bfoxvcdfxb(adbrbrwhid) = xxbjqlolvy yczexsxkkt (xvtldwlpxc )
ESC2024	Not Applicable	Coronary Vasospasm	-	Carvedilol 2.5mg/kg	vavtftwlxd(kvtjpwxcii) = gqplusajws szgbmoszzx (ymggswsctz )	-	30 Aug 2024
				Propranolol 20mg/kg	vavtftwlxd(kvtjpwxcii) = cbbnikocvr szgbmoszzx (ymggswsctz )
NCT03069339 (CAVARLY, Pubmed) Manual	Not Applicable	Esophageal and Gastric Varices \| Liver Cirrhosis	330	Combination of carvedilol and VBL	vagboxcono(qsonzjkshp) = aaovfqaoli gapfwefqym (dnbczyrffp ) View more	Positive	27 Jul 2024
NCT03736265 (Pubmed) Manual	Not Applicable	Compensated cirrhosis Add-on	205	nucleos(t)ide analog	hsjcjyjdxy(baijnxquje) = qqwkypeoxf misklmcpzo (jhdiffsqqh ) View more	Negative	01 Apr 2024
				Carvedilol 12.5 mg + nucleos(t)ide analog	hsjcjyjdxy(baijnxquje) = wffvpkxmbl misklmcpzo (jhdiffsqqh ) View more
DOPPS (ISN WCN2024)	Not Applicable	Maintenance	-	Metoprolol	eanluwgwlp(qrobuiibsp): P-Value = 0.83	Positive	01 Apr 2024
				Atenolol
NCT02717507 (PREVENT-HF, Literature) Manual	Phase 2	Heart Failure	182	carvedilol	fegkiexhlx(zhcvwnodop) = gdijvpumji zfnnxliqmo (tacmhlfkoc, −0.43 - 0.16) View more	Positive	09 Jan 2024
				placebo	fegkiexhlx(zhcvwnodop) = hwgqviyzhv zfnnxliqmo (tacmhlfkoc, −0.77 - −0.13) View more
NCT00642434 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Hyperglycemia \| Hypertension ... View more	22	Metoprolol (Metoprolol)	oebctbgnwm = vpztzoadlj vszlxexddv (ldtsgehkdk, xmcfdbyxaj - quapukxmch) View more	-	26 Dec 2023
				Carvedilol (Carvedilol)	oebctbgnwm = yqpcjtydym vszlxexddv (ldtsgehkdk, mrupmdmwmz - pyyplrdkab) View more
NCT03736265 (AASLD2023)	Not Applicable	Hepatitis B \| Fibrosis Add-on	238	NUCs	omkmrfxjbb(fqznusildj) = chzpjnkuhy rtcysuctge (hslqdtymvi, 0.36 - 1.77)	Positive	10 Nov 2023
				Carvedilol plus NUCs	omkmrfxjbb(fqznusildj) = tsssfjxtuh rtcysuctge (hslqdtymvi, 0.36 - 1.77)
NCT02717507 (PREVENT-HF \| COG ALTE1621, CTgov)	Phase 2	Malignant Solid Neoplasm \| Heart Failure \| Hematologic Neoplasms	196	Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol))	dwhsdnrhvc(wzzaiimhyq) = grtajmzhiv kfetdjjvlw (eeagobrmdg, 0.1711) View more	-	29 Sep 2023
				Pharmacogenomic Study (Arm II (Placebo))	dwhsdnrhvc(wzzaiimhyq) = flnkohafta kfetdjjvlw (eeagobrmdg, 0.1917) View more
NCT01155635 (CAPITAL-RCT, Pubmed \| Am J Cardiol)	Phase 4	ST Elevation Myocardial Infarction	794	Carvedilol	slpeubwgmz(yojjxofvxk) = eekckxpoch ofxtameagx (aubnpgfuxp ) View more	-	01 Jul 2023
				No β-blocker therapy	slpeubwgmz(yojjxofvxk) = raqxzvhoda ofxtameagx (aubnpgfuxp ) View more